Alembic gets FDA tentative OK for generic Bosulif
Bosutinib tablets are indicated for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.
The Food and Drug Administration has granted Alembic tentative approval for Bosutinib Tablets, 100 mg and 500 mg, which is the generic of PF Prism’s Bosulif Tablets.
Bosutinib Tablets are indicated for the treatment of a certain type of leukemia called Philadelphia chromosome-positive chronic myelogenous leukemia.
Alembic releases generic Pradaxa
Bosutinib Tablets, 100 mg and 500 mg have a market value of roughly $ 275 million for the 12 months ending March 2024, per IQVIA.
[Read more: Alembic intros generic Perforomist]